13 results
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
29 Jun 21
Regulation FD Disclosure
7:30am
– Efficacy: pathologic, physiologic, functional and clinical markers Target Recruitment Patients will roll in from ongoing prospective natural history
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
28 Jun 21
Regulation FD Disclosure
7:33am
– Efficacy: pathologic, physiologic, functional and clinical markers Target Recruitment 14 subjects injected 5 years old Target Areas to Transduce … Secondary – Efficacy: pathologic, physiologic, functional and clinical markers Target Recruitment Up to 6 subjects Age younger than or equal to 12 months
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
14 Apr 21
Regulation FD Disclosure
4:20pm
-dosed gene therapy Goals Target Recruitment Target Areas to Transduce Primary – Safety: clinical and laboratory assessments 14 subjects injected
10-K
axrc8m1vwcn1lb
3 Mar 21
Annual report
9:00am
10-Q
sul65ixlzht91mqyjh
12 Nov 20
Quarterly report
4:27pm
424B4
e1ru6o 89s1uxeb
25 Sep 20
Prospectus supplement with pricing info
12:00am
S-1/A
y8el6ako4za3c
8 Sep 20
IPO registration (amended)
4:43pm
S-1
48pkbcktmm1suk5iq8
2 Sep 20
IPO registration
5:02pm
DRS
ny0p88 4dl1soxbyn
3 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next